Merck Receives Breakthrough Therapy Designation For Keytruda In Chl
April 18, 2016 at 11:42 AM EDT
Merck announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to KEYTRUDA, the company's anti-PD-1 therapy, for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma.
